Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ACI-7104.056

Vaccine (Peptide vaccine) · Immune activation

Phase 2 Most advanced trial
1 Registered trials

What is ACI-7104.056?

ACI-7104.056 is an adjuvanted protein peptide conjugate vaccine being studied in Parkinson disease, including early-onset forms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Peptide vaccine)
Mechanism
Immune activation
Therapy area
Neurology
In trials of
ACIU
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06015841 Phase 2 Parkinson Disease Active not recruiting ACIU

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Parkinson DiseaseParkinson Disease 6, Early-Onset

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.